Details of the Drug Combination

General Information of Drug Combination (ID: DCWDY5M)

Drug Combination Name
Gefitinib Topotecan
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs Gefitinib   DM15F0X Topotecan   DMP6G8T
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HS 578T
Zero Interaction Potency (ZIP) Score: 4.6
Bliss Independence Score: 5.91
Loewe Additivity Score: 9.79
LHighest Single Agent (HSA) Score: 10.54

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gefitinib
Disease Entry ICD 11 Status REF
Colon adenocarcinoma N.A. Approved [2]
Glioblastoma 2A00 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Rectal adenocarcinoma 2B92 Approved [2]
Rectum mucinous adenocarcinoma N.A. Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Head and neck cancer 2D42 Phase 3 [3]
Urethral cancer 2C93 Phase 2 [3]
Colon cancer 2B90.Z Investigative [2]
Colon mucinous adenocarcinoma N.A. Investigative [2]
Gefitinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [13]
------------------------------------------------------------------------------------
Gefitinib Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [15]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [16]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Gefitinib Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [17]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [18]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [17]
------------------------------------------------------------------------------------
Gefitinib Interacts with 64 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases ADR [19]
Sulfhydryl oxidase 1 (QSOX1) OT4ZPK4P QSOX1_HUMAN Increases Expression [20]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Decreases Expression [20]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [20]
Fibroblast growth factor 6 (FGF6) OTRJ679P FGF6_HUMAN Increases Expression [20]
Ski oncogene (SKI) OT4KJ8F6 SKI_HUMAN Increases Expression [20]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Expression [20]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Decreases Expression [20]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [20]
Replication protein A 70 kDa DNA-binding subunit (RPA1) OT76POLP RFA1_HUMAN Increases Expression [20]
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Decreases Expression [20]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Decreases Expression [20]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [20]
Epidermal growth factor receptor substrate 15 (EPS15) OT7NPP8U EPS15_HUMAN Increases Expression [20]
Neural retina-specific leucine zipper protein (NRL) OT65MFKQ NRL_HUMAN Decreases Expression [20]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 (GNB2) OT3JPRCQ GBB2_HUMAN Decreases Expression [20]
Retinal guanylyl cyclase 1 (GUCY2D) OT81UJI0 GUC2D_HUMAN Decreases Expression [20]
Cell growth regulator with RING finger domain protein 1 (CGRRF1) OTLMNRCL CGRF1_HUMAN Increases Expression [20]
Dual specificity protein phosphatase 9 (DUSP9) OTZZWEQL DUS9_HUMAN Decreases Expression [20]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [21]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [22]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [23]
Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) OTVT4YA1 ATG7_HUMAN Increases Expression [24]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [25]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Phosphorylation [26]
HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA) OTZE5Q7R DOA_HUMAN Affects Expression [27]
Heat shock protein HSP 90-alpha (HSP90AA1) OTLG1WPK HS90A_HUMAN Increases Secretion [28]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [29]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Secretion [30]
DnaJ homolog subfamily B member 1 (DNAJB1) OTCOSEVH DNJB1_HUMAN Increases Secretion [28]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Expression [31]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Expression [31]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [32]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Affects Expression [27]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [23]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Increases Expression [25]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [9]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [32]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Response To Substance [33]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [29]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [34]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Expression [35]
MHC class I polypeptide-related sequence B (MICB) OTS2DVDW MICB_HUMAN Increases Expression [36]
MHC class I polypeptide-related sequence A (MICA) OTPEIEAR MICA_HUMAN Increases Expression [36]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [27]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [24]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [37]
MARVEL domain-containing protein 1 (MARVELD1) OT5CPOJE MALD1_HUMAN Decreases Response To Substance [38]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Affects Response To Substance [39]
Membrane-associated progesterone receptor component 1 (PGRMC1) OTBE6WAC PGRC1_HUMAN Decreases Response To Substance [40]
RNA-binding protein 7 (RBM7) OTFIWTMF RBM7_HUMAN Affects Response To Substance [41]
Cell death regulator Aven (AVEN) OTGIN5YK AVEN_HUMAN Affects Response To Substance [41]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Increases Response To Substance [42]
Phospholipase B-like 1 (PLBD1) OTHYEB4W PLBL1_HUMAN Affects Response To Substance [41]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Decreases Response To Substance [29]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Affects Response To Substance [41]
DNA excision repair protein ERCC-1 (ERCC1) OTNPYQHI ERCC1_HUMAN Affects Response To Substance [12]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [43]
Ceramide transfer protein (CERT1) OTNUCNHX CERT_HUMAN Affects Response To Substance [41]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Affects Response To Substance [41]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Response To Substance [44]
Pericentrin (PCNT) OTW4Z65J PCNT_HUMAN Decreases Response To Substance [40]
Coronin-1C (CORO1C) OTXDF9T3 COR1C_HUMAN Affects Response To Substance [41]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Affects Response To Substance [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 64 DOT(s)
Indication(s) of Topotecan
Disease Entry ICD 11 Status REF
Central nervous system neoplasm N.A. Approved [4]
Cervical cancer 2C77.0 Approved [4]
Epithelial ovarian cancer 2B5D Approved [4]
Lung cancer 2C25.0 Approved [4]
Ovarian cancer 2C73 Approved [5]
Solid tumour/cancer 2A00-2F9Z Approved [6]
Small-cell lung cancer 2C25.Y Phase 1 [7]
Neuroblastoma 2D11.2 Investigative [4]
Topotecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Modulator [48]
------------------------------------------------------------------------------------
Topotecan Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [49]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [50]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [51]
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [52]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [53]
Multidrug and toxin extrusion protein 2 (SLC47A2) DT3TX4H S47A2_HUMAN Substrate [52]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Topotecan Interacts with 183 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [54]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Response To Substance [55]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [56]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [57]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [58]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [59]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [60]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Cleavage [54]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [57]
Tumor protein 63 (TP63) OT0WOOKQ P63_HUMAN Decreases Expression [58]
Bcl-2-like protein 12 (BCL2L12) OTS6IFZY B2L12_HUMAN Decreases Expression [60]
Three-prime repair exonuclease 1 (TREX1) OTQG7K12 TREX1_HUMAN Increases Expression [56]
Histone H2A.V (H2AZ2) OT0I5H2P H2AV_HUMAN Affects Response To Substance [46]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) OT0KMIYQ RIPK2_HUMAN Affects Response To Substance [46]
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial (BCKDHA) OT0LHOZB ODBA_HUMAN Affects Response To Substance [46]
Secreted frizzled-related protein 1 (SFRP1) OT0U9G41 SFRP1_HUMAN Affects Response To Substance [46]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [46]
Tetraspanin-8 (TSPAN8) OT1F68WQ TSN8_HUMAN Affects Response To Substance [46]
Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) OT1G9297 TFIP8_HUMAN Affects Response To Substance [46]
Optineurin (OPTN) OT2UXWH9 OPTN_HUMAN Affects Response To Substance [46]
Protein FAM171A1 (FAM171A1) OT33BHEP F1711_HUMAN Affects Response To Substance [46]
Filamin-C (FLNC) OT3F8J6Y FLNC_HUMAN Affects Response To Substance [46]
Cleavage stimulation factor subunit 2 tau variant (CSTF2T) OT3IKRL2 CSTFT_HUMAN Affects Response To Substance [46]
Fatty acid CoA ligase Acsl3 (ACSL3) OT3MWER1 ACSL3_HUMAN Affects Response To Substance [46]
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 (PIN4) OT403QC1 PIN4_HUMAN Affects Response To Substance [46]
C-Jun-amino-terminal kinase-interacting protein 4 (SPAG9) OT45AHMB JIP4_HUMAN Affects Response To Substance [46]
Sorcin (SRI) OT4R3EAC SORCN_HUMAN Affects Response To Substance [46]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A) OT4RF9Z4 PDE8A_HUMAN Affects Response To Substance [46]
Argininosuccinate synthase (ASS1) OT4ZMG0Q ASSY_HUMAN Affects Response To Substance [46]
Polyphosphoinositide phosphatase (FIG4) OT501PY9 FIG4_HUMAN Affects Response To Substance [46]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Affects Response To Substance [46]
Leukocyte elastase inhibitor (SERPINB1) OT5RDUFO ILEU_HUMAN Affects Response To Substance [46]
Collagen alpha-2(V) chain (COL5A2) OT5VOSQE CO5A2_HUMAN Decreases Response To Substance [47]
Transcription activator BRG1 (SMARCA4) OT68WOPQ SMCA4_HUMAN Affects Response To Substance [46]
Metal cation symporter ZIP8 (SLC39A8) OT6C6MNV S39A8_HUMAN Affects Response To Substance [46]
Regulator of G-protein signaling 20 (RGS20) OT6CGYHW RGS20_HUMAN Affects Response To Substance [46]
BTB/POZ domain-containing protein KCTD3 (KCTD3) OT6EGR42 KCTD3_HUMAN Affects Response To Substance [46]
Melanoma-associated antigen D1 (MAGED1) OT6EOLFC MAGD1_HUMAN Affects Response To Substance [46]
Ferritin heavy chain (FTH1) OT6IFS0O FRIH_HUMAN Affects Response To Substance [46]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2) OT6MFOWF TGM2_HUMAN Affects Response To Substance [46]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Affects Response To Substance [46]
Cytochrome b5 (CYB5A) OT6SN4RM CYB5_HUMAN Affects Response To Substance [46]
Ankycorbin (RAI14) OT6USGBK RAI14_HUMAN Affects Response To Substance [46]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [46]
Replication protein A 70 kDa DNA-binding subunit (RPA1) OT76POLP RFA1_HUMAN Affects Response To Substance [46]
Signal transducer CD24 (CD24) OT7CODJ4 CD24_HUMAN Affects Response To Substance [46]
Polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) OT7M67WT GALT3_HUMAN Affects Response To Substance [46]
Forkhead box protein D1 (FOXD1) OT80PRHS FOXD1_HUMAN Affects Response To Substance [46]
Cbp/p300-interacting transactivator 2 (CITED2) OT812TV7 CITE2_HUMAN Affects Response To Substance [46]
Raftlin (RFTN1) OT8875JE RFTN1_HUMAN Affects Response To Substance [46]
Mesoderm-specific transcript homolog protein (MEST) OT8Q4U8Y MEST_HUMAN Affects Response To Substance [46]
Four-jointed box protein 1 (FJX1) OT8SVTSS FJX1_HUMAN Affects Response To Substance [46]
Calmodulin-regulated spectrin-associated protein 2 (CAMSAP2) OT9KXWE7 CAMP2_HUMAN Affects Response To Substance [46]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3) OTA2TBWS HMGN3_HUMAN Affects Response To Substance [46]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4) OTA6ICI2 NUD4B_HUMAN Affects Response To Substance [46]
SEC14-like protein 1 (SEC14L1) OTA75FET S14L1_HUMAN Affects Response To Substance [46]
Autism susceptibility gene 2 protein (AUTS2) OTAEXHSC AUTS2_HUMAN Affects Response To Substance [46]
Grancalcin (GCA) OTAJ7ZHG GRAN_HUMAN Affects Response To Substance [46]
RNA polymerase II elongation factor ELL3 (ELL3) OTALC1YD ELL3_HUMAN Affects Response To Substance [46]
Receptor-type tyrosine-protein phosphatase kappa (PTPRK) OTAP5AT3 PTPRK_HUMAN Affects Response To Substance [46]
snRNA-activating protein complex subunit 1 (SNAPC1) OTAPN1NI SNPC1_HUMAN Affects Response To Substance [46]
Cyclin-dependent kinase inhibitor 1C (CDKN1C) OTASTJ3Q CDN1C_HUMAN Affects Response To Substance [46]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Affects Response To Substance [46]
Desmoplakin (DSP) OTB2MOP8 DESP_HUMAN Affects Response To Substance [46]
Protein lin-7 homolog C (LIN7C) OTB3015O LIN7C_HUMAN Affects Response To Substance [46]
Heterogeneous nuclear ribonucleoprotein D-like (HNRNPDL) OTB3BFCV HNRDL_HUMAN Affects Response To Substance [46]
Microtubule-associated tumor suppressor 1 (MTUS1) OTBPALMU MTUS1_HUMAN Affects Response To Substance [46]
Cilium assembly protein DZIP1 (DZIP1) OTBVPO66 DZIP1_HUMAN Affects Response To Substance [46]
Thiamin pyrophosphokinase 1 (TPK1) OTCHPUD0 TPK1_HUMAN Affects Response To Substance [46]
Cytoskeleton-associated protein 2 (CKAP2) OTCLTC0J CKAP2_HUMAN Affects Response To Substance [46]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Affects Response To Substance [46]
Tetraspanin-13 (TSPAN13) OTCS9BZY TSN13_HUMAN Affects Response To Substance [46]
Tropomyosin alpha-1 chain (TPM1) OTD73X6R TPM1_HUMAN Affects Response To Substance [46]
AP-5 complex subunit mu-1 (AP5M1) OTDLWEBL AP5M1_HUMAN Affects Response To Substance [46]
Protein eva-1 homolog B (EVA1B) OTDNAKQD EVA1B_HUMAN Affects Response To Substance [46]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Affects Response To Substance [46]
Ras-related protein Rab-7L1 (RAB29) OTDZT6LP RAB7L_HUMAN Affects Response To Substance [46]
H(+)/Cl(-) exchange transporter 3 (CLCN3) OTEEXNMU CLCN3_HUMAN Affects Response To Substance [46]
Secernin-1 (SCRN1) OTELM5C2 SCRN1_HUMAN Affects Response To Substance [46]
NGFI-A-binding protein 1 (NAB1) OTEWHIZR NAB1_HUMAN Affects Response To Substance [46]
Solute carrier family 35 member G2 (SLC35G2) OTFBVS0P S35G2_HUMAN Affects Response To Substance [46]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Affects Response To Substance [46]
Multiple C2 and transmembrane domain-containing protein 2 (MCTP2) OTFMZ8I2 MCTP2_HUMAN Affects Response To Substance [46]
Caveolae-associated protein 1 (CAVIN1) OTFO915U CAVN1_HUMAN Affects Response To Substance [46]
Laminin subunit alpha-2 (LAMA2) OTFROQWE LAMA2_HUMAN Increases Response To Substance [47]
Centriolar satellite-associated tubulin polyglutamylase complex regulator 1 (CSTPP1) OTFSO3XV CSTP1_HUMAN Affects Response To Substance [46]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Affects Response To Substance [46]
Transmembrane protein 80 (TMEM80) OTG9D4KX TMM80_HUMAN Affects Response To Substance [46]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1) OTGPN3P8 TIA1_HUMAN Affects Response To Substance [46]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Affects Response To Substance [46]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [46]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Affects Response To Substance [46]
Solute carrier family 38 member 6 (SLC38A6) OTIC8SHQ S38A6_HUMAN Affects Response To Substance [46]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Affects Response To Substance [46]
Laminin subunit gamma-1 (LAMC1) OTIG527N LAMC1_HUMAN Affects Response To Substance [46]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Affects Response To Substance [46]
Beta/gamma crystallin domain-containing protein 1 (CRYBG1) OTIPDI15 CRBG1_HUMAN Affects Response To Substance [46]
Ras-related protein Rab-13 (RAB13) OTIQ484I RAB13_HUMAN Affects Response To Substance [46]
Ankyrin repeat domain-containing protein 10 (ANKRD10) OTIZ2VK8 ANR10_HUMAN Affects Response To Substance [46]
Histone deacetylase complex subunit SAP18 (SAP18) OTJAZWOL SAP18_HUMAN Affects Response To Substance [46]
E3 ubiquitin-protein ligase FANCL (FANCL) OTJC7QPQ FANCL_HUMAN Affects Response To Substance [46]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH) OTJDOL20 HCDH_HUMAN Affects Response To Substance [46]
FERM domain-containing protein 4A (FRMD4A) OTJDTIK2 FRM4A_HUMAN Affects Response To Substance [46]
Cyclin-F (CCNF) OTJFVU43 CCNF_HUMAN Affects Response To Substance [46]
Jupiter microtubule associated homolog 2 (JPT2) OTJGPA4T JUPI2_HUMAN Affects Response To Substance [46]
TBC1 domain family member 4 (TBC1D4) OTK66C40 TBCD4_HUMAN Affects Response To Substance [46]
Tumor necrosis factor receptor superfamily member 6B (TNFRSF6B) OTKAN9G7 TNF6B_HUMAN Affects Response To Substance [46]
Myelin protein zero-like protein 2 (MPZL2) OTKFNDUI MPZL2_HUMAN Affects Response To Substance [46]
Transmembrane channel-like protein 6 (TMC6) OTKH50J4 TMC6_HUMAN Affects Response To Substance [46]
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2) OTKOZRZP PLOD2_HUMAN Affects Response To Substance [46]
Enolase-phosphatase E1 (ENOPH1) OTKXMWNN ENOPH_HUMAN Affects Response To Substance [46]
Calcium-binding tyrosine phosphorylation-regulated protein (CABYR) OTKYMT99 CABYR_HUMAN Affects Response To Substance [46]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2) OTLNA39Z NMT2_HUMAN Affects Response To Substance [46]
Hemicentin-1 (HMCN1) OTLZAS0P HMCN1_HUMAN Increases Response To Substance [47]
Ribosome biogenesis protein BOP1 (BOP1) OTMZMQDO BOP1_HUMAN Affects Response To Substance [46]
Eukaryotic peptide chain release factor GTP-binding subunit ERF3B (GSPT2) OTN0K7F3 ERF3B_HUMAN Affects Response To Substance [46]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Affects Response To Substance [46]
MAP kinase-interacting serine/threonine-protein kinase 2 (MKNK2) OTNA9G8V MKNK2_HUMAN Affects Response To Substance [46]
Epithelial splicing regulatory protein 1 (ESRP1) OTNCS4SL ESRP1_HUMAN Affects Response To Substance [46]
Radixin (RDX) OTNSYUN6 RADI_HUMAN Affects Response To Substance [46]
Calcium-activated potassium channel subunit alpha-1 (KCNMA1) OTNYXOZO KCMA1_HUMAN Affects Response To Substance [46]
Paraneoplastic antigen-like protein 8A (PNMA8A) OTO3F7B0 PNM8A_HUMAN Affects Response To Substance [46]
Polypeptide N-acetylgalactosaminyltransferase 1 (GALNT1) OTO3RO36 GALT1_HUMAN Affects Response To Substance [46]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Affects Response To Substance [46]
Unconventional myosin-Id (MYO1D) OTP2RGPN MYO1D_HUMAN Affects Response To Substance [46]
Rho GTPase-activating protein 7 (DLC1) OTP8LMCR RHG07_HUMAN Affects Response To Substance [46]
Ras-related protein Rab-20 (RAB20) OTP9OOVS RAB20_HUMAN Affects Response To Substance [46]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Affects Response To Substance [46]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [46]
Pentraxin-related protein PTX3 (PTX3) OTPXHRKU PTX3_HUMAN Affects Response To Substance [46]
Dermatan-sulfate epimerase (DSE) OTQ108VJ DSE_HUMAN Affects Response To Substance [46]
Centromere protein U (CENPU) OTQ4TZRS CENPU_HUMAN Affects Response To Substance [46]
Sortilin-related receptor (SORL1) OTQ8FFNS SORL_HUMAN Affects Response To Substance [46]
Collagen alpha-2(VI) chain (COL6A2) OTQC6PPO CO6A2_HUMAN Affects Response To Substance [46]
Ran-specific GTPase-activating protein (RANBP1) OTQE226K RANG_HUMAN Affects Response To Substance [46]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [46]
Keratin, type I cytoskeletal 23 (KRT23) OTQW6UAG K1C23_HUMAN Increases Response To Substance [47]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Response To Substance [47]
Large ribosomal subunit protein mL63 (MRPL57) OTRB659E RT63_HUMAN Affects Response To Substance [46]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Affects Response To Substance [46]
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) OTRHPFO2 AN32A_HUMAN Affects Response To Substance [46]
Calcium/calmodulin-dependent protein kinase type 1 (CAMK1) OTRN55RE KCC1A_HUMAN Affects Response To Substance [46]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Affects Response To Substance [46]
Arginine and glutamate-rich protein 1 (ARGLU1) OTRVRZ4Z ARGL1_HUMAN Affects Response To Substance [46]
Dr1-associated corepressor (DRAP1) OTRWLF6D NC2A_HUMAN Affects Response To Substance [46]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [46]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Affects Response To Substance [46]
Lumican (LUM) OTSRC874 LUM_HUMAN Decreases Response To Substance [47]
GTP-binding protein SAR1a (SAR1A) OTSSRVGV SAR1A_HUMAN Affects Response To Substance [46]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Affects Response To Substance [46]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Decreases Response To Substance [47]
KH domain-containing RNA-binding protein QKI (QKI) OTTAUGLB QKI_HUMAN Affects Response To Substance [46]
Cullin-4A (CUL4A) OTTBV70J CUL4A_HUMAN Affects Response To Substance [46]
Homeobox protein Hox-B2 (HOXB2) OTTD6HMV HXB2_HUMAN Affects Response To Substance [46]
Collagen alpha-1(XV) chain (COL15A1) OTTFKK18 COFA1_HUMAN Decreases Response To Substance [47]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Affects Response To Substance [46]
Nuclear receptor-interacting protein 3 (NRIP3) OTU15GMK NRIP3_HUMAN Affects Response To Substance [46]
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha (CSF2RA) OTUOO2XS CSF2R_HUMAN Affects Response To Substance [46]
La-related protein 6 (LARP6) OTUQ9QS9 LARP6_HUMAN Affects Response To Substance [46]
General transcription factor II-I (GTF2I) OTUYL1TQ GTF2I_HUMAN Affects Response To Substance [46]
Protein aurora borealis (BORA) OTV2ZPKP BORA_HUMAN Affects Response To Substance [46]
FYVE, RhoGEF and PH domain-containing protein 1 (FGD1) OTV3T64P FGD1_HUMAN Affects Response To Substance [46]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Decreases Response To Substance [47]
Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 (MACF1) OTVIHD77 MACF1_HUMAN Affects Response To Substance [46]
Serine protease FAM111A (FAM111A) OTVLARLG F111A_HUMAN Affects Response To Substance [46]
Interleukin-1 receptor accessory protein-like 1 (IL1RAPL1) OTW3T4B2 IRPL1_HUMAN Affects Response To Substance [46]
Tissue alpha-L-fucosidase (FUCA1) OTW71IK4 FUCO_HUMAN Affects Response To Substance [46]
Fanconi anemia group I protein (FANCI) OTW8E3SC FANCI_HUMAN Affects Response To Substance [46]
U2 small nuclear ribonucleoprotein A' (SNRPA1) OTWJZFAP RU2A_HUMAN Affects Response To Substance [46]
Methyl-CpG-binding domain protein 4 (MBD4) OTWR9YXE MBD4_HUMAN Affects Response To Substance [46]
ORC ubiquitin ligase 1 (OBI1) OTX62ZHW OBI1_HUMAN Affects Response To Substance [46]
Condensin complex subunit 2 (NCAPH) OTXOS97C CND2_HUMAN Affects Response To Substance [46]
Collagen alpha-2(I) chain (COL1A2) OTY7G382 CO1A2_HUMAN Increases Response To Substance [47]
Collagen alpha-1(VI) chain (COL6A1) OTYKSCOB CO6A1_HUMAN Affects Response To Substance [46]
Protein FAN (NSMAF) OTYNVZ23 FAN_HUMAN Affects Response To Substance [46]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Affects Response To Substance [46]
Nucleolar complex protein 3 homolog (NOC3L) OTYOR3PV NOC3L_HUMAN Affects Response To Substance [46]
Acetyl-CoA acetyltransferase, cytosolic (ACAT2) OTZ092ZJ THIC_HUMAN Affects Response To Substance [46]
Thiosulfate sulfurtransferase (TST) OTZ4F5LK THTR_HUMAN Affects Response To Substance [46]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [46]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Affects Response To Substance [46]
Suppressor of tumorigenicity 7 protein (ST7) OTZG8RC6 ST7_HUMAN Affects Response To Substance [46]
Fermitin family homolog 2 (FERMT2) OTZNPWWX FERM2_HUMAN Affects Response To Substance [46]
------------------------------------------------------------------------------------
⏷ Show the Full List of 183 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ovarian Cancer DC7V5UU N. A. Phase 1 [61]
Adenocarcinoma DCWQBCG OVCAR3 Investigative [62]
Adult T acute lymphoblastic leukemia DC28B19 MOLT-4 Investigative [62]
Cutaneous melanoma DCLL989 SK-MEL-28 Investigative [62]
Glioma DCFC9RK SF-268 Investigative [62]
High grade ovarian serous adenocarcinoma DC1GVT3 OVCAR-4 Investigative [62]
High grade ovarian serous adenocarcinoma DCLDHBI OVCAR-8 Investigative [62]
Melanoma DC4A1AD UACC-257 Investigative [62]
Mixed endometrioid and clear cell carcinoma DCKB3V5 IGROV1 Investigative [62]
Ovarian serous cystadenocarcinoma DC4HSLM SK-OV-3 Investigative [62]
Papillary renal cell carcinoma DCPRZC4 ACHN Investigative [62]
Pleural epithelioid mesothelioma DCRQ68K NCI-H226 Investigative [62]
Prostate carcinoma DCKM2IX PC-3 Investigative [62]
Breast adenocarcinoma DCRRP41 MDA-MB-468 Investigative [1]
Carcinoma DC6T4MD MCF7 Investigative [1]
Colon adenocarcinoma DC540ZY COLO 205 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2 Gefitinib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
4 Topotecan FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7101).
6 Plant-derived compounds in clinical trials. Drug Discov Today. 2008 Feb;13(3-4):161-71.
7 ClinicalTrials.gov (NCT00765973) Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors. U.S. National Institutes of Health.
8 Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther. 2008 Mar;7(3):599-606.
9 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
10 EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother. 2011 May;34(4):372-81. doi: 10.1097/CJI.0b013e31821b724a.
11 Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. Arch Toxicol. 2019 Jun;93(6):1555-1571. doi: 10.1007/s00204-019-02453-2. Epub 2019 Apr 16.
12 DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer. 2011 Jul 15;117(14):3201-8. doi: 10.1002/cncr.25863. Epub 2011 Jan 24.
13 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
14 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
15 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
16 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
17 Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
18 Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
19 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
20 Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
21 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
22 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
23 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
24 EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
25 ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
26 Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005 Oct 15;11(20):7480-9. doi: 10.1158/1078-0432.CCR-05-0328.
27 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
28 Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
29 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
30 Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
31 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
32 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
33 The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
34 Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
35 Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016 Nov 1;310:140-149. doi: 10.1016/j.taap.2016.09.010. Epub 2016 Sep 14.
36 Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci. 2012 Jan;103(1):7-16. doi: 10.1111/j.1349-7006.2011.02109.x. Epub 2011 Nov 15.
37 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
38 Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
39 Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9. doi: 10.1164/rccm.201009-1440OC. Epub 2010 Oct 29.
40 Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):359-73. doi: 10.1016/j.taap.2015.08.008. Epub 2015 Aug 20.
41 Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15;13(24):3029-43. doi: 10.1093/hmg/ddh331. Epub 2004 Oct 20.
42 The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3169-79. doi: 10.1158/1535-7163.MCT-07-0507.
43 BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17.
44 Aurora-A promotes gefitinib resistance via a NF-B signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun. 2011 Feb 11;405(2):168-72. doi: 10.1016/j.bbrc.2011.01.001. Epub 2011 Jan 7.
45 Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. 2005 Jun 1;65(11):4775-81. doi: 10.1158/0008-5472.CAN-04-3332.
46 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
47 Microarray-based detection and expression analysis of extracellular matrix proteins in drug?resistant ovarian cancer cell lines. Oncol Rep. 2014 Nov;32(5):1981-90. doi: 10.3892/or.2014.3468. Epub 2014 Sep 9.
48 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
49 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
50 Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
51 Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
52 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
53 Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab. 2006 Jan;7(1):105-18.
54 Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters. Biochem Pharmacol. 2010 Aug 15;80(4):471-9. doi: 10.1016/j.bcp.2010.04.038. Epub 2010 May 8.
55 Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999 Dec 1;59(23):5938-46.
56 Human three prime exonuclease TREX1 is induced by genotoxic stress and involved in protection of glioma and melanoma cells to anticancer drugs. Biochim Biophys Acta. 2013 Aug;1833(8):1832-43. doi: 10.1016/j.bbamcr.2013.03.029. Epub 2013 Apr 8.
57 Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells. Biochem Pharmacol. 2015 Apr 1;94(3):212-9. doi: 10.1016/j.bcp.2015.01.012. Epub 2015 Feb 7.
58 p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells. Biochem Pharmacol. 2013 Apr 1;85(7):999-1006. doi: 10.1016/j.bcp.2013.01.019. Epub 2013 Jan 29.
59 Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. Mol Pharmacol. 2008 Aug;74(2):517-26. doi: 10.1124/mol.107.043620. Epub 2008 May 20.
60 Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006 Dec;387(12):1629-33. doi: 10.1515/BC.2006.203.
61 ClinicalTrials.gov (NCT00317772) Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
62 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966